2019至2023年法国产KPC肠杆菌目细菌的流行病学特征
该研究对2019至2023年法国国家抗菌药物耐药中心收到的419株产KPC肠杆菌目细菌进行表型和基因组分析。结果显示产KPC菌约占所有产碳青霉烯酶肠杆菌目的2%,以KPC-3为主(78%),ST307为优势序列型(39.4%)并关联法国北部大规模暴发,克隆多样化明显。
要点
- 产KPC肠杆菌目占所有产碳青霉烯酶肠杆菌目约2%,以KPC-3(78%)和KPC-2(21%)为主。
- ST307占39.4%并关联法国北部大暴发,ST147和ST512亦常见,克隆多样化显著。
- 头孢他啶-阿维巴坦、亚胺培南-瑞来巴坦和美罗培南-伐博巴坦体外活性高(敏感率97.8%、95.8%、97.9%)。
核心结论
- 法国国家参考中心收到的产KPC肺炎克雷伯菌呈现明显克隆多样化,并出现耐药与毒力汇聚的菌株,需持续基因组监测。
研究设计与样本
- 研究纳入2019至2023年法国国家抗菌药物耐药中心接收的419株产KPC肠杆菌目细菌,采用肉汤微量稀释法进行药敏试验,对404株进行全基因组测序,并通过AMR基因检测、MLST和基于SNP的系统发育分析耐药机制、克隆结构和暴发动态。
主要发现
- 产KPC肠杆菌目约占所有产碳青霉烯酶肠杆菌目的2%。
- 肺炎克雷伯菌复合种占86%(363/419)。
- KPC-3占78%(328/419),KPC-2占21%(87/419),11株检出其他碳青霉烯酶。
- 353株肺炎克雷伯菌基因组MLST鉴定出45个序列型,ST307占39.4%并关联法国北部大暴发,ST147占8.8%,ST512占7.6%。
关键数值与推荐
- 头孢他啶-阿维巴坦体外敏感率为97.8%。
- 亚胺培南-瑞来巴坦体外敏感率为95.8%。
- 美罗培南-伐博巴坦体外敏感率为97.9%。
临床怎么用
- 对产KPC肠杆菌目感染,头孢他啶-阿维巴坦、亚胺培南-瑞来巴坦和美罗培南-伐博巴坦体外活性高,可作为治疗参考。
- ST307等克隆的局部暴发提示需结合基因组监测指导感染防控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The global spread of Klebsiella pneumoniae carbapenemase (KPC)-type carbapenemases has historically been driven by clonal group CG258, but increasing clonal diversification has recently been reported. We aimed to provide a comprehensive phenotypic and genomic characterization of KPC-producing Enterobacterales referred to French National Center (NRC) for Antimicrobial Resistance between 2019 and 2023. MATERIALS AND METHODS: A total of 419 KPC-producing Enterobacterales were referred to the French NRC for Antimicrobial Resistance. Antimicrobial susceptibility testing was performed by broth microdilution. Whole-genome sequencing was conducted for 404 isolates. AMR gene detection, MLST and SNP-based phylogeny were used to analyse resistance mechanisms, clonal structure and outbreak dynamics. RESULTS: KPC-producing Enterobacterales accounted for ∼2% of all carbapenemase-producing Enterobacterales. The K. pneumoniae species complex represented 86% (363/419) of isolates. KPC-3 predominated (328/419, 78%), followed by KPC-2 (87/419, 21%). Additional carbapenemases were detected in 11 isolates. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam showed high in vitro activity (97.8%, 95.8% and 97.9% susceptibility, respectively). MLST of 353 K. pneumoniae genomes identified 45 sequence types (STs); ST307 predominated (39.4%) and was associated with a major outbreak in northern France. ST147 (8.8%) and ST512 (7.6%) were also prevalent. Fifteen isolates from ST11, ST39, ST101, and ST395 had high virulence score of 4 (iuc-positive). CONCLUSIONS: KPC-producing K. pneumoniae referred to the French NRC show marked clonal diversification. The emergence of resistant isolates and convergent resistance-virulence profiles underscore the need for sustained genomic surveillance.
引用
- Rouabah L, Ronsin S, Vasseur A, et al. Epidemiology of KPC-producing Enterobacterales isolated from 2019 to 2023 in France. J Antimicrob Chemother. 2026. PMID: 42585275. doi:10.1093/jac/dkag273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。